School of Medicine
Showing 1-10 of 24 Results
-
Mable Lam
Instructor, Neurosurgery
Current Research and Scholarly InterestsMyelin is required for rapid nerve signaling by insulating axons to accelerate action potential propagation. Myelin-forming cells of the central nervous system, called oligodendrocytes, orchestrate one of the most complex morphological transformations in neurobiology. Each oligodendrocyte can extend multiple processes that selectively wrap axons in tens to hundreds of spiraling membrane layers, forming myelin sheaths that vary in thickness and length. Furthermore, oligodendrocytes can respond to neural activity by adding new sheaths or by changing the geometry of pre-existing sheaths to tune neural circuitry, a process known as adaptive myelination.
What are the membrane trafficking mechanisms that drive adaptive myelination in oligodendrocytes?
How can these mechanisms be stimulated to promote myelin regeneration in disease?
By using transgenic mouse models and primary oligodendrocytes, we have found that SNARE-mediated exocytosis drives membrane addition in myelin sheaths. Current research is focused on how these pathways in oligodendrocytes may be regulated during adaptive myelination. -
Maarten Lansberg, MD, PhD
Professor of Neurology and Neurological Sciences (Adult Neurology) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsMy research involves the design and conduct of clinical trials to discover new treatments for patients who have suffered a stroke. These trials span treatment of acute stroke, stroke recovery, and stroke prevention. My research in acute stroke is primarily focused on the use of advanced neuroimaging methods (CT and MRI) to select patients who are most likely to benefit from therapies aimed at restoring blood flow to the brain in patients who have suffered a stroke.
-
Jin Hyung Lee
Associate Professor of Neurology and Neurological Sciences (Neurology Research), of Neurosurgery and of Bioengineering and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsIn vivo visualization and control of neural circuits
-
Sukmook Lee
Visiting Professor, Neurosurgery
BioProfessor Sukmook Lee, Ph.D., is a distinguished expert in the field of antibody engineering and therapeutic antibody development. He currently serves as the Director of the Antibody Research Institute and Professor in the Department of Biopharmaceutical Chemistry at Kookmin University. Additionally, he holds a Visiting Professorship in the Department of Neurosurgery at Stanford University School of Medicine. His cutting-edge research is globally recognized, particularly for its focus on immunological disorders, infectious diseases, and cancer therapies.
As the head of the Innovative Antibodies Laboratory (InnoAbs), a globally leading research group, Professor Lee spearheads pioneering efforts to develop novel therapeutic antibodies. His lab’s work has made significant strides in cancer immunotherapy, COVID-19 treatment, and the creation of diagnostic antibodies for COVID-19. The InnoAbs Lab also collaborates extensively with academic and industrial partners to drive innovation in therapeutic targeting, cancer progression, and metastasis.
Professor Lee is widely recognized in the scientific community, serving on the editorial boards of high-impact journals such as Scientific Reports, Antibodies, and Frontiers in Bioscience. He also contributes as a bio-advisory board member for leading pharmaceutical companies, including Samsung Biologics, Samsung Bioepis, ISU Abxis, and Ankook Pharmaceutical. His extensive consulting work for both international and domestic industries highlights his pivotal role in bridging academic research with practical medical applications. In addition, he serves as a steering committee member for the Korean Society for Biochemistry and Molecular Biology (KSBMB) and the Antibody Society of Korea (ASK), and is an active member of The Antibody Society and the American Association for Cancer Research (AACR) in the USA.
A visionary researcher, Professor Lee continues to push the boundaries of modern medicine, particularly through his efforts to commercialize groundbreaking antibody platforms for cancer and viral therapies, bringing new hope to patients worldwide.
